FOLH1 and prostate carcinoma: In 2020 Italian Regulatory Agency AIFA approved our clinical trial “Experimental study to evaluate the impact of 18F-PSMA PET/CT in the management of patients with prostate cancer” EudraCT 2019-002000-41.